Immune response in irritable bowel syndrome: A systematic review of systemic and mucosal inflammatory mediators

Journal of Digestive Diseases

Volumn 17, Issue 9, 2016, Pages 572-581

  Martin Viñas, Juan J ^a   Quigley, Eamonn M M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Cytokine; Enterochromaffin cell; Interleukin; Irritable bowel syndrome; Mast cell; T lymphocyte

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR; AUTACOID; CYTOKINE;

CD3+ T LYMPHOCYTE; ENTEROCHROMAFFIN CELL; HUMAN; IMMUNE RESPONSE; INTESTINE MUCOSA; IRRITABLE COLON; MAST CELL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SYSTEMATIC REVIEW; IMMUNOLOGY; METABOLISM; MUCOSAL IMMUNITY; T LYMPHOCYTE SUBPOPULATION;

CYTOKINES; ENTEROCHROMAFFIN CELLS; HUMANS; IMMUNITY, MUCOSAL; INFLAMMATION MEDIATORS; INTESTINAL MUCOSA; IRRITABLE BOWEL SYNDROME; MAST CELLS; T-LYMPHOCYTE SUBSETS;

EID: 85016771991     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/1751-2980.12379     Document Type: Review

References (97)

1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
2. Saito YA, Schoenfeld P, Locke GR 3rd. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 2002; 97: 1910-5.
3. Choung RS, Locke GR 3rd. Epidemiology of IBS. Gastroenterol Clin North Am 2011; 40: 1-10.
4. Hulisz D. The burden of illness of irritable bowel syndrome: current challenges and hope for the future. J Manag Care Pharm 2004; 10: 299-309.
5. Collins SM. Is the irritable gut an inflamed gut? Scand J Gastroenterol Suppl 1992; 192: 102-5.
6. Spiller RC, Jenkins D, Thornley JP et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47: 804-11.
7. Bercik P, Verdu EF, Collins SM. Is irritable bowel syndrome a low-grade inflammatory bowel disease? Gastroenterol Clin North Am 2005; 34: 235-45.
8. Barbara G, Stranghellini V, DeGiorgio R et al. Activated mast cells in proximity to colonic nerves correlates with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693-702.
9. Talley NJ, Spiller R. Irritable bowel syndrome: a little understood organic bowel disease? Lancet 2002; 360: 555-64.
10. Crowell MD, Shetzline MA, Moses PL, Mawe GM, Talley NJ. Enterochromaffin cells and 5-HT signaling the pathophysiology of disorders of gastrointestinal function. Curr Opin Investig Drugs 2004; 5: 55-60.
11. Coates MD, Mahoney CR, Linden DR et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004; 126: 1657-64.
12. Chadwick VS, Chen W, Shu D et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122: 1778-83.
13. Singh RK, Pandey HP, Singh RH. Correlation of serotonin and monoamine oxidase levels with anxiety level in diarrheapredominant irritable bowel syndrome. Indian J Gastroenterol 2003; 22: 88-90.
14. Dunlop SP, Coleman NS, Blackshaw E et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3: 349-57.
15. Dinan TG, Quigley EM, Ahmed SM et al. Hypothalamicpituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 2006; 130: 304-11.
16. Chang L, Adeyemo M, Karagiannides I et al. Serum and colonic mucosal immune markers in irritable bowel syndrome. Am J Gastroenterol 2012; 107: 262-72.
17. Hughes PA, Zola H, Penttila IA, Blackshaw LA, Andrews JM, Krumbiegel D. Immune activation in irritable bowel syndrome: can neuroimmune interactions explain symptoms? Am J Gastroenterol 2013; 108: 1066-74.
18. Romero-Valdovinos M, Gudiño-Ramírez A, Reyes-Gordillo J et al. Interleukin-8 and-10 gene polymorphisms in irritable bowel syndrome. Mol Biol Rep 2012; 39: 8837-43.
19. Dinan TG, Clarke G, Quigley EM et al. Enhanced cholinergicmediated increase in the pro-inflammatory cytokine IL-6 in irritable bowel syndrome: role of muscarinic receptors. Am J Gastroenterol 2008; 103: 2570-6.
20. Hua MC, Lai MW, Kuo ML, Yao TC, Huang JL, Chen SM. Decreased interleukin-10 secretion by peripheral blood mononuclear cells in children with irritable bowel syndrome. J Pediatr Gastroenterol Nutr 2011; 52: 376-81.
21. van der Veek PP, van den Berg M, de Kroon YE, Verspaget HW, Masclee AA. Role of tumor necrosis factor-α and interleukin-10 gene polymorphisms in irritable bowel syndrome. Am J Gastroenterol 2005; 100: 2510-6.
22. Wang SH, Dong L, Luo JY et al. Decreased expression of serotonin in the jejunum and increased numbers of mast cells in the terminal ileum in patients with irritable bowel syndrome. World J Gastroenterol 2007; 13: 6041-7.
23. Macsharry J, O’Mahony L, Fanning A et al. Mucosal cytokine imbalance in irritable bowel syndrome. Scand J Gastroenterol 2008; 43: 1467-76.
24. McKernan DP, Gaszner G, Quigley EM, Cryan JF, Dinan TG. Altered peripheral toll-like receptor responses in the irritable bowel syndrome. Aliment Pharmacol Ther 2011; 33: 1045-52.
25. Cenac N, Andrews CN, Holzhausen M et al. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 2007; 117: 636-47.
26. Brint EK, MacSharry J, Fanning A, Shanahan F, Quigley EM. Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol 2011; 106: 329-36.
27. Cremon C, Carini G, Wang B et al. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol 2011; 106: 1290-8.
28. Coëffier M, Gloro R, Boukhettala N et al. Increased proteasome-mediated degradation of occludin in irritable bowel syndrome. Am J Gastroenterol 2010; 105: 1181-8.
29. Lee KJ, Kim YB, Kim JH, Kwon HC, Kim DK, Cho SW. The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. J Gastroenterol Hepatol 2008; 23: 1689-94.
30. Gwee KA, Collins SM, Read NW et al. Increased rectal mucosal expression of interleukin 1β in recently acquired postinfectious irritable bowel syndrome. Gut 2003; 52: 523-6.
31. Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003; 125: 1651-9.
32. Buhner S, Li Q, Vignali S et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology 2009; 137: 1425-34.
33. Goral V, Kucukoner M, Buyukbayram H. Mast cells count and serum cytokine levels in patients with irritable bowel syndrome. Hepatogastroenterology 2010; 57: 751-4.
34. Gecse K, Róka R, Ferrier L et al. Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity. Gut 2008; 57: 591-9.
35. Scully P, McKernan DP, Keohane J et al. Plasma cytokine profiles in females with irritable bowel syndrome and extraintestinal co-morbidity. Am J Gastroenterol 2010; 105: 2235-43.
36. Kindt S, Van Oudenhove L, Broekaert D et al. Immune dysfunction in patients with functional gastrointestinal disorders. Neurogastroenterol Motil 2009; 21: 389-98.
37. Swan C, Duroudier NP, Campbell E et al. Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFα. Gut 2013; 62: 985-94.
38. De Silva AP, Nandasiri SD, Hewavisenthi J et al. Subclinical mucosal inflammation in diarrhea-predominant irritable bowel syndrome (IBS) in a tropical setting. Scand J Gastroenterol 2012; 47: 619-24.
39. Lee H, Park JH, Park DI et al. Mucosal mast cell count is associated with intestinal permeability in patients with diarrhea predominant irritable bowel syndrome. J Neurogastroenterol Motil 2013; 19: 244-50.
40. Wilcz-Villega EM, McClean S, O’Sullivan MA. Mast cell tryptase reduces junctional adhesion molecule-A (JAM-A) expression in intestinal epithelial cells: implications for the mechanisms of barrier dysfunction in irritable bowel syndrome. Am J Gastroenterol 2013; 108: 1140-51.
41. El-Salhy M, Gundersen D, Hatlebakk JG, Hausken T. Lowgrade inflammation in the rectum of patients with sporadic irritable bowel syndrome. Mol Med Rep 2013; 7: 1081-5.
42. Balestra B, Vicini R, Cremon C et al. Colonic mucosal mediators from patients with irritable bowel syndrome excite enteric cholinergic motor neurons. Neurogastroenterol Motil 2012; 24: 1118-e570.
43. Martínez C, Lobo B, Pigrau M et al. Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier. Gut 2013; 62: 1160-8.
44. Willot S, Gauthier C, Patey N, Faure C. Nerve growth factor content is increased in the rectal mucosa of children with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 2012; 24: 734-9, e347.
45. Braak B, Klooker TK, Wouters MM et al. Mucosal immune cell numbers and visceral sensitivity in patients with irritable bowel syndrome: is there any relationship? Am J Gastroenterol 2012; 107: 715-26.
46. Arévalo F, Aragon V, Montes P, Guzmán E, Monge E. Increase of intraepithelial lymphocytes in patients with irritable bowel syndrome. Rev Gastroenterol Peru 2011; 31: 315-8 (in Spanish).
47. Martínez C, Vicario M, Ramos L et al. The jejunum of diarrheapredominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations. Am J Gastroenterol 2012; 107: 736-46.
48. Han W, Wang Z, Lu X, Guo C. Protease activated receptor 4 status of mast cells in post infectious irritable bowel syndrome. Neurogastroenterol Motil 2012; 24: 113-9, e82.
49. Frieling T, Meis K, Kolck UW et al. Evidence for mast cell activation in patients with therapy-resistant irritable bowel syndrome. Z Gastroenterol 2011; 49: 191-4.
50. Bhuiyan MR, Majumder TK, Raihan AA, Roy PK, Farha N, Kamal M. Histopathological alterations in post-infectious irritable bowel syndrome in Bangladeshi population. Mymensingh Med J 2010; 19: 275-81.
51. Cremon C, Gargano L, Morselli-Labate AM et al. Mucosal immune activation in irritable bowel syndrome: genderdependence and association with digestive symptoms. Am J Gastroenterol 2009; 104: 392-400.
52. Guilarte M, Santos J, de Torres I et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 2007; 56: 203-9.
53. Park JH, Rhee PL, Kim HS et al. Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome. J Gastroenterol Hepatol 2006; 21: 71-8.
54. Park CH, Joo YE, Choi SK, Rew JS, Kim SJ, Lee MC. Activated mast cells infiltrate in close proximity to enteric nerves in diarrhea-predominant irritable bowel syndrome. J Korean Med Sci 2003; 18: 204-10.
55. O’Sullivan M, Clayton N, Breslin NP et al. Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil 2000; 12: 449-57.
56. Yang Y, Zhou D, Zhang W, Zhang Z, Song Y. Mast cells of ileocecal junction in irritable bowel syndrome. Chin J Intern Med 1997; 36: 231-3 (in Chinese).
57. Weston AP, Biddle WL, Bhatia PS, Miner PB Jr. Terminal ileal mucosal mast cells in irritable bowel syndrome. Dig Dis Sci 1993; 38: 1590-5.
58. Ohman L, Lindmark AC, Isaksson S et al. Increased TLR2 expression on blood monocytes in irritable bowel syndrome patients. Eur J Gastroenterol Hepatol 2012; 24: 398-405.
59. Barkhordari E, Rezaei N, Mahmoudi M et al. T-helper 1, T-helper 2, and T-regulatory cytokines gene polymorphisms in irritable bowel syndrome. Inflammation 2010; 33: 281-6.
60. Fu Y, Tong JJ, Pan Q et al. Phenotypic analysis of Th cells in colon and peripheral blood in patients with irritable bowel syndrome. Natl Med J China 2009; 89: 2120-3 (in Chinese).
61. Kim HS, Lim JH, Park H, Lee SI. Increased immunoendocrine cells in intestinal mucosa of postinfectious irritable bowel syndrome patients 3 years after acute Shigella infection-an observation in a small case control study. Yonsei Med J 2010; 51: 45-51.
62. Ohman L, Isaksson S, Lindmark AC et al. T-cell activation in patients with irritable bowel syndrome. Am J Gastroenterol 2009; 104: 1205-12.
63. Ohman L, Lindmark AC, Isaksson S et al. B-cell activation in patients with irritable bowel syndrome (IBS). Neurogastroenterol Motil 2009; 21: 644-e27.
64. Jin HB, Gu ZY, Zhao HW, Wang QY, Wu W, Li YM. T lymphocyte subgroups and serum levels of trace elements in patients with diarrhea type of irritable bowel syndrome. J Zhengjiang Univ (Med Sci) 2008; 37: 634-7 (in Chinese).
65. Forshammar J, Isaksson S, Strid H et al. A pilot study of colonic B cell pattern in irritable bowel syndrome. Scand J Gastroenterol 2008; 43: 1461-6.
66. Liebregts T, Adam B, Bredack C et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007; 132: 913-20.
67. O’Mahony L, McCarthy J, Kelly P et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541-51.
68. Elsenbruch S, Holtmann G, Oezcan D et al. Are there alterations of neuroendocrine and cellular immune responses to nutrients in women with irritable bowel syndrome? Am J Gastroenterol 2004; 99: 703-10.
69. Törnblom H, Lindberg G, Nyberg B, Veress B. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002; 123: 1972-9.
70. Del Valle-Pinero AY, Martino AC, Taylor TJ et al. Proinflammatory chemokine C-C motif ligand 16 (CCL-16) dysregulation in irritable bowel syndrome (IBS): a pilot study. Neurogastroenterol Motil 2011; 23: 1092-7.
71. Zucchelli M, Camilleri M, Andreasson AN et al. Association of TNFSF15 polymorphism with irritable bowel syndrome. Gut 2011; 60: 1671-7.
72. Gao J. Correlation between anxiety-depression status and cytokines in diarrhea-predominant irritable bowel syndrome. Exp Ther Med 2013; 6: 93-6.
73. Rana SV, Sharma S, Sinha SK, Parsad KK, Malik A, Singh K. Pro-inflammatory and anti-inflammatory cytokine response in diarrhoea-predominant irritable bowel syndrome patients. Trop Gastroenterol 2012; 33: 251-6.
74. Belmonte L, Beutheu Youmba S, Bertiaux-Vandaële N et al. Role of toll like receptors in irritable bowel syndrome: differential mucosal immune activation according to the disease subtype. PLoS One 2012; 7: e42777.
75. Bashashati M, Rezaei N, Bashashati H et al. Cytokine gene polymorphisms are associated with irritable bowel syndrome: a systematic review and meta-analysis. Neurogastroenterol Motil 2012; 24: 1102-e566.
76. Chen J, Zhang Y, Deng Z. Imbalanced shift of cytokine expression between T helper 1 and T helper 2 (Th1/Th2) in intestinal mucosa of patients with post-infectious irritable bowel syndrome. BMC Gastroenterol 2012; 12: 91.
77. Schmulson M, Pulido-London D, Rodriguez O et al. Lower serum IL-10 is an independent predictor of IBS among volunteers in Mexico. Am J Gastroenterol 2012; 107: 747-53.
78. Bashashati M, Rezaei N, Shafieyoun A et al. Cytokine imbalance in irritable bowel syndrome: a systematic review and meta-analysis. Neurogastroenterol Motil 2014; 26: 1036-48.
79. Fitzgerald P, Cassidy Eugene M, Clarke G et al. Tryptophan catabolism in females with irritable bowel syndrome: relationship to interferon-gamma, severity of symptoms and psychiatric co-morbidity. Neurogastroenterol Motil 2008; 20: 1291-7.
80. Felger JC, Lotrich FE. Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience 2013; 246: 199-229.
81. Kurosawa N, Shimizu K, Seki K. The development of depression-like behavior is consolidated by IL-6-induced activation of locus coeruleus neurons and IL-1β-induced elevated leptin levels in mice. Psychopharmacology (Berl) 2016; 233: 1725-37.
82. Ganança L, Oquendo MA, Tyrka AR, Cisneros-Trujillo S, Mann JJ, Sublette ME. The role of cytokines in the pathophysiology of suicidal behavior. Psychoneuroendocrinology 2016; 63: 296-310.
83. Dahl J, Ormstad H, Aass HC et al. The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery. Psychoneuroendocrinology 2014; 45: 77-86.
84. Doyle LA, Sepehr GJ, Hamilton MJ, Akin C, Castells MC, Hornick JL. A clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients. Am J Surg Pathol 2014; 38: 832-43.
85. Hess A, Roesch J, Saake M et al. Functional brain imaging reveals rapid blockade of abdominal pain response upon anti-TNF therapy in Crohn’s disease. Gastroenterology 2015; 149: 864-6.
86. Dunlop SP, Jenkins D, Neal KR et al. Randomized, doubleblind, placebo-controlled trial of prednisolone in postinfectious irritable bowel syndrome. Aliment Pharmacol Ther 2003; 18: 77-84.
87. Lam C, Tan W, Leighton M et al. A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D). Gut 2016; 65: 91-9.
88. Barbara G, Cremon C, Annese V et al. Randomised controlled trial of mesalazine in IBS. Gut 2016; 65: 82-90.
89. Klooker TK, Braak B, Koopman KE et al. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut 2010; 59: 1213-21.
90. Rizzo A, Fiorentino M, Buommino E, Donnarumma G, Losacco A, Bevilacqua N. Lactobacillus crispatus mediates antiinflammatory cytokine interleukin-10 induction in response to Chlamydia trachomatis infection in vitro. Int J Med Microbiol 2015; 305: 815-27.
91. Konieczna P, Groeger D, Ziegler M et al. Bifidobacterium infantis 35624 administration induces Foxp3 1 T regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells. Gut 2012; 61: 354-66.
92. Groeger D, O’Mahony L, Murphy EF et al. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes 2013; 4: 325-39.
93. Jalanka J, Salonen A, Fuentes S, de Vos WM. Microbial signatures in post-infectious irritable bowel syndrome-towards patient stratification for improved diagnostics and treatment. Gut Microbes 2015; 6: 364-9.
94. Mujagic Z, Ludidi S, Keszthelyi D et al. Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders. Aliment Pharmacol Ther 2014; 40: 288-97.
95. Fukudo S. Role of corticotropin-releasing hormone in irritable bowel syndrome and intestinal inflammation. J Gastroenterol 2007; 42 (Suppl 17): 48-51.
96. Pimentel M, Morales W, Rezaie A et al. Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects. PLoS One 2015; 10: e0126438.
97. Lembo AJ, Neri B, Tolley J, Barken D, Carroll S, Pan H. Use of serum biomarkers in a diagnostic test for irritable bowel syndrome. Aliment Pharmacol Ther 2009; 29: 834-42.